Nazia Karsan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Nazia Karsan has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Peter James Goadsby
King Abdullah University of Science and Technology
20 shared publications Peter J. Goadsby
Headache Group, NIHR King’s Clinical Research Facility and SLaM Biomedical Research Centre, The Wolfson Sensory, Pain and Regeneration Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
4 shared publications- Ray Pyari Bose
NeuralConnexion Specialist Neurology Services Auckland New Zealand
3 shared publications - Gianluca Coppola
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy
2 shared publications - Helin Gosalia
Headache Group, The Wolfson Sensory, Pain and Rehabilitation Centre, NIHR King’s Clinical Research Facility, & SLaM Biomedical Research Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London SE5 9PJ, UK
2 shared publications Jayde Newman
Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
2 shared publications
Latest Publications
- Open Access
- 11 August 2026
- Published by European Medical Group in EMJ Neurology
- Vol. 14 (1) , 75-79
Does Migraine with Aura Require Different Treatment Strategies Compared to Migraine Without Aura?
Migraine has two main forms: migraine with aura (MwA) and migraine without aura (MwoA).1 The former is less common and only affects...
- 11 August 2026
- Published by European Medical Group in EMJ Neurology
- Vol. 14 (1) , 75-79
Open AccessDoes Migraine with Aura Require Different Treatment Strategies Compared to Migraine Without Aura?
Migraine has two main forms: migraine with aura (MwA) and migraine without aura (MwoA).1 The former is less common and only affects...
- Open Access
- 6 August 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (8)
Migraine and headache in children and adolescents: A 2026 evidence-based factsheet
Background: Headache disorders, particularly migraine, are among the leading causes of disability worldwide, with onset frequently occurring during childhood and adolescence. Despite their high prevalence and substantial functional impact, paediatric headache disorders remain under-recognised within health systems and under-represented in global policy frameworks. Methods: This factsheet was developed to provide a comprehensive, developmentally informed overview of the global burden of headache disorders in children and adolescents. It synthesises evidence from population-based studies, systematic reviews, clinical cohorts, and Global Burden of Disease (GBD) 2023 estimates. Key domains include epidemiology, disability burden, functional and psychosocial impacts, risk factors and triggers, diagnostic and treatment gaps, and current management strategies, with particular attention to disparities across sociodemographic groups. Results: According to GBD 2023 point-prevalence estimates, headache disorders increase markedly across development, from 10.71% among children aged 5–9 years to 42.64% among adolescents aged 15–19 years. Corresponding migraine prevalence estimates increase from 2.79% to 18.08%. GBD 2023 data also indicate that migraine is among the leading causes of years lived with disability from early life onwards.Migraine in children and adolescents is associated with substantial impairment in school attendance, academic performance, social participation, and quality of life. It is also frequently accompanied by psychiatric and somatic comorbidities. Access to timely diagnosis and evidence-based treatment remains highly inequitable, particularly in low- and middle-income countries. Emerging evidence suggests that adolescence may represent a critical window for intervention, with the potential to reduce progression to chronic migraine and long-term disability. Conclusions: Migraine and other headache disorders in children and adolescents constitute a major global public health challenge. This factsheet provides a comprehensive, evidence-based summary of their burden and highlights urgent priorities for policy integration, advocacy, and research. Early, equitable, and developmentally tailored care is essential to reduce lifelong disability and improve global brain health outcomes.
- 6 August 2026
- Published by SAGE Publications in Cephalalgia
- Vol. 46 (8)
Open AccessMigraine and headache in children and adolescents: A 2026 evidence-based factsheet
Background: Headache disorders, particularly migraine, are among the leading causes of disability worldwide, with onset frequently occurring during childhood and adolescence. Despite their high prevalence and substantial functional impact, paediatric headache disorders remain under-recognised within health systems and under-represented in global policy frameworks. Methods: This factsheet was developed to provide a comprehensive, developmentally informed overview of the global burden of headache disorders in children and adolescents. It synthesises evidence from population-based studies, systematic reviews, clinical cohorts, and Global Burden of Disease (GBD) 2023 estimates. Key domains include epidemiology, disability burden, functional and psychosocial impacts, risk factors and triggers, diagnostic and treatment gaps, and current management strategies, with particular attention to disparities across sociodemographic groups. Results: According to GBD 2023 point-prevalence estimates, headache disorders increase markedly across development, from 10.71% among children aged 5–9 years to 42.64% among adolescents aged 15–19 years. Corresponding migraine prevalence estimates increase from 2.79% to 18.08%. GBD 2023 data also indicate that migraine is among the leading causes of years lived with disability from early life onwards.Migraine in children and adolescents is associated with substantial impairment in school attendance, academic performance, social participation, and quality of life. It is also frequently accompanied by psychiatric and somatic comorbidities. Access to timely diagnosis and evidence-based treatment remains highly inequitable, particularly in low- and middle-income countries. Emerging evidence suggests that adolescence may represent a critical window for intervention, with the potential to reduce progression to chronic migraine and long-term disability. Conclusions: Migraine and other headache disorders in children and adolescents constitute a major global public health challenge. This factsheet provides a comprehensive, evidence-based summary of their burden and highlights urgent priorities for policy integration, advocacy, and research. Early, equitable, and developmentally tailored care is essential to reduce lifelong disability and improve global brain health outcomes.
- Open Access
- 26 October 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (3) , 595-603
Evaluating associations of migraine‐related vertigo
Objective: We set out to examine detailed phenotypic data from our clinic for associations of vertigo in chronic migraine. Background: Vertigo is a non‐canonical, common symptom of migraine. Little is known about its associations with other symptoms within the migraine phenotype. There is significant methodological heterogeneity and therefore inadequate overall evidence about the potential differences in efficacy of any migraine treatments in patients with problematic vertigo associated with migraine, compared to those without vertigo. Enhancing understanding of migraine‐related vertigo could help guide treatment and inform on mechanisms of vestibular migraine, a poorly understood diagnostic entity. Methods: Chronic migraine extended phenotypes of patients seen within the adult headache service at King's College Hospital Tertiary Headache Service between January 2014 and December 2021 ( n = 589) were extracted from the first documented clinic consultation letter retrospectively. For those with information about vertigo ( n = 562), potential associations of interest for the presence of vertigo (gender, allodynia, aura, photophobia, phonophobia and osmophobia, baseline headache frequency, number of premonitory symptoms, presence of cranial autonomic symptoms, and age) were analyzed using a regression model (IBM SPSS v 29). Missing data were excluded (final n = 435). Results: The total sample size for analysis in the regression model was n = 435, after excluding missing data ( n = 126) and outliers ( n = 1). Patients were 16–92 years old (median, 47; interquartile range, 37–55), and the majority (83.4%) were female. Vertigo associated with migraine was present in 275 of 562 (49%) patients. Within the regression model, the presence of aura (odds ratio, 2.13; 95% confidence interval, 1.4–3.23, P < 0.001) and allodynia (odds ratio, 2.74; 95% confidence interval, 1.76–4.26, P < 0.001) were positively associated with vertigo. Conclusions: Vertigo in chronic migraine is common and may be associated with a more enriched phenotype independent of baseline headache frequency. Future treatment strategies should be evaluated for their effects on this often under‐recognized yet disabling symptom.
- 26 October 2025
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 66 (3) , 595-603
Open AccessEvaluating associations of migraine‐related vertigo
Objective: We set out to examine detailed phenotypic data from our clinic for associations of vertigo in chronic migraine. Background: Vertigo is a non‐canonical, common symptom of migraine. Little is known about its associations with other symptoms within the migraine phenotype. There is significant methodological heterogeneity and therefore inadequate overall evidence about the potential differences in efficacy of any migraine treatments in patients with problematic vertigo associated with migraine, compared to those without vertigo. Enhancing understanding of migraine‐related vertigo could help guide treatment and inform on mechanisms of vestibular migraine, a poorly understood diagnostic entity. Methods: Chronic migraine extended phenotypes of patients seen within the adult headache service at King's College Hospital Tertiary Headache Service between January 2014 and December 2021 ( n = 589) were extracted from the first documented clinic consultation letter retrospectively. For those with information about vertigo ( n = 562), potential associations of interest for the presence of vertigo (gender, allodynia, aura, photophobia, phonophobia and osmophobia, baseline headache frequency, number of premonitory symptoms, presence of cranial autonomic symptoms, and age) were analyzed using a regression model (IBM SPSS v 29). Missing data were excluded (final n = 435). Results: The total sample size for analysis in the regression model was n = 435, after excluding missing data ( n = 126) and outliers ( n = 1). Patients were 16–92 years old (median, 47; interquartile range, 37–55), and the majority (83.4%) were female. Vertigo associated with migraine was present in 275 of 562 (49%) patients. Within the regression model, the presence of aura (odds ratio, 2.13; 95% confidence interval, 1.4–3.23, P < 0.001) and allodynia (odds ratio, 2.74; 95% confidence interval, 1.76–4.26, P < 0.001) were positively associated with vertigo. Conclusions: Vertigo in chronic migraine is common and may be associated with a more enriched phenotype independent of baseline headache frequency. Future treatment strategies should be evaluated for their effects on this often under‐recognized yet disabling symptom.
- Open Access
- 6 June 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (6)
Cortical thickness studies in migraine: Current evidence and future directions
Background: Structural imaging offers insight into migraine pathogenesis. Magnetic resonance imaging (MRI) morphometry plays a crucial role in identifying these alterations, yet the clinical significance remains debated. While gray matter volume and cortical curvature are commonly analyzed, cortical thickness offers a more direct measure of cytoarchitectural differences and neuroplastic changes in migraine. Advanced structural MRI techniques, including surface-based morphometry and voxel-based morphometry, have provided insights into cortical thickness alterations in migraine. These methods enable high-resolution assessment of brain morphometry, revealing dynamic changes associated with migraine phases and treatment. Methods: This narrative review synthesizes findings from cortical thickness studies, focusing on methodological approaches, variations in imaging sequences and study designs, including cross-sectional and longitudinal studies. Results: Studies using surface-based morphometry (i.e. SBM) and voxel-based morphometry (i.e. VBM) have reported inconsistent findings. Increased thickness is frequently observed in pain-processing regions, such as the somatosensory cortex, insula and anterior cingulate cortex reflecting hyperexcitability or maladaptive neuroplasticity. by contrast, cortical thinning has been noted in regions such as the orbitofrontal cortex, posterior cingulate cortex and visual cortex, suggesting neuronal loss or impaired cortical integrity. Differences between episodic and chronic migraine further highlight progressive structural changes associated with disease burden. Emerging evidence also suggests that preventive treatments, including calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A, may reverse some of these cortical alterations, particularly in treatment responders. Conclusions: Cortical thickness analysis provides valuable insights into migraine pathophysiology, offering a potential biomarker for disease progression and treatment response. However, inconsistencies across studies highlight the need for standardized MRI protocols and larger longitudinal investigations to clarify the clinical relevance of cortical thickness changes in migraine.
- 6 June 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (6)
Open AccessCortical thickness studies in migraine: Current evidence and future directions
Background: Structural imaging offers insight into migraine pathogenesis. Magnetic resonance imaging (MRI) morphometry plays a crucial role in identifying these alterations, yet the clinical significance remains debated. While gray matter volume and cortical curvature are commonly analyzed, cortical thickness offers a more direct measure of cytoarchitectural differences and neuroplastic changes in migraine. Advanced structural MRI techniques, including surface-based morphometry and voxel-based morphometry, have provided insights into cortical thickness alterations in migraine. These methods enable high-resolution assessment of brain morphometry, revealing dynamic changes associated with migraine phases and treatment. Methods: This narrative review synthesizes findings from cortical thickness studies, focusing on methodological approaches, variations in imaging sequences and study designs, including cross-sectional and longitudinal studies. Results: Studies using surface-based morphometry (i.e. SBM) and voxel-based morphometry (i.e. VBM) have reported inconsistent findings. Increased thickness is frequently observed in pain-processing regions, such as the somatosensory cortex, insula and anterior cingulate cortex reflecting hyperexcitability or maladaptive neuroplasticity. by contrast, cortical thinning has been noted in regions such as the orbitofrontal cortex, posterior cingulate cortex and visual cortex, suggesting neuronal loss or impaired cortical integrity. Differences between episodic and chronic migraine further highlight progressive structural changes associated with disease burden. Emerging evidence also suggests that preventive treatments, including calcitonin gene-related peptide monoclonal antibodies and botulinum toxin A, may reverse some of these cortical alterations, particularly in treatment responders. Conclusions: Cortical thickness analysis provides valuable insights into migraine pathophysiology, offering a potential biomarker for disease progression and treatment response. However, inconsistencies across studies highlight the need for standardized MRI protocols and larger longitudinal investigations to clarify the clinical relevance of cortical thickness changes in migraine.
- Open Access
- 29 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Evaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine
Background: Our knowledge of the presence and type of premonitory symptoms in patients with cluster headache is limited. Methods: Premonitory symptom presence and type in a clinical cohort of cluster headache and migraine was collated retrospectively from clinical notes, alongside a cluster headache nitroglycerin triggered experimental group and an age-matched migraine nitroglycerin experimental group. Demographic data and premonitory symptoms in cluster headache and migraine patients were analysed. The primary focus was on premonitory symptom presence and phenotype in cluster headache patients, with secondary analysis exploring associated factors and comparing spontaneous and nitroglycerin-triggered symptoms in cluster headache and migraine cohorts. Results: Among 164 cluster headache patients, 122/164 (74%) males, aged 45.9 ± 13.8 years (mean ± SD), 66/164 (40%) had chronic cluster headache and 32/164 (20%) had also comorbid migraine. Among them, 85% exhibited premonitory symptoms for which the presence was associated with oxygen treatment. No significant differences were found in symptom frequency between cluster headache and migraine cohorts or within spontaneous and nitroglycerin-triggered symptoms. Conclusions: This study highlights recognizable spontaneous and nitroglycerin-triggered premonitory symptoms in cluster headache and factors potentially impacting cluster headache management, which may aid in tailoring treatment strategies for both conditions through the use of treatment prediction and early intervention.
- 29 April 2025
- Published by SAGE Publications in Cephalalgia
- Vol. 45 (4)
Open AccessEvaluation of premonitory spontaneous and nitroglycerin triggered symptoms among patients with cluster headache and migraine
Background: Our knowledge of the presence and type of premonitory symptoms in patients with cluster headache is limited. Methods: Premonitory symptom presence and type in a clinical cohort of cluster headache and migraine was collated retrospectively from clinical notes, alongside a cluster headache nitroglycerin triggered experimental group and an age-matched migraine nitroglycerin experimental group. Demographic data and premonitory symptoms in cluster headache and migraine patients were analysed. The primary focus was on premonitory symptom presence and phenotype in cluster headache patients, with secondary analysis exploring associated factors and comparing spontaneous and nitroglycerin-triggered symptoms in cluster headache and migraine cohorts. Results: Among 164 cluster headache patients, 122/164 (74%) males, aged 45.9 ± 13.8 years (mean ± SD), 66/164 (40%) had chronic cluster headache and 32/164 (20%) had also comorbid migraine. Among them, 85% exhibited premonitory symptoms for which the presence was associated with oxygen treatment. No significant differences were found in symptom frequency between cluster headache and migraine cohorts or within spontaneous and nitroglycerin-triggered symptoms. Conclusions: This study highlights recognizable spontaneous and nitroglycerin-triggered premonitory symptoms in cluster headache and factors potentially impacting cluster headache management, which may aid in tailoring treatment strategies for both conditions through the use of treatment prediction and early intervention.
- Open Access
- 26 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3023
Glutamate as a Therapeutic Substrate in Migraine
Recurrent and intense headache is a well appreciated cardinal feature of migraine, a common and incapacitating neurological disorder. Often, there are associated canonical sensory abnormalities, such as light and sound sensitivity, as well as associated nausea. Given this phenotype of disordered sensory processing and, in a third of patients, the phenomenon called aura accompanying migraine attacks, it has been suggested that the pathophysiology of migraine is likely to involve glutamate, the main excitatory neurotransmitter in the central nervous system (CNS). Glutamate plays a role in nociception, central sensitization, and cortical spreading depression (CSD), three processes that are deemed important in migraine biology. With an emphasis on the therapeutic potential of targeting various glutamate receptors in migraine, this review will discuss the currently available literature and emerging findings on the role of targeting glutamatergic pathways for the treatment of migraine. A thorough literature review was carried out on the functions of both metabotropic glutamate receptors (mGluRs), and the ionotropic glutamate receptors (NMDA, AMPA, and kainate) in migraine pathogenesis. The ever-present need for new treatments, the role of glutamate in the migraine aura phenomenon, and the consequences of monogenic migraine mutations on mediating prolonged, complex, or permanent aura are all discussed, culminating in a suggestion that glutamatergic targeting may hold particular promise in the management of migraine aura. There are plausible roles for metabotropic receptors in regulating pain processing in important migraine-related brain structures, like the thalamus and trigeminal nucleus. Similarly, ionotropic receptors contribute to excitatory neurotransmission and neuronal hyperexcitability. Recent studies have shown preclinical and early clinical results for treatments targeting these receptors, but there are still significant issues with treatment response, including drug transport, side effects, and efficacy. With ongoing and emerging discoveries in the field, there is increasing promise of new migraine medications targeting glutamate receptors. For bench to bedside translation in this area, continued study of the molecular basis of migraine, receptor subtypes, and exploration of potential drug delivery methods are needed.
- 26 March 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (7) , 3023
Open AccessGlutamate as a Therapeutic Substrate in Migraine
Recurrent and intense headache is a well appreciated cardinal feature of migraine, a common and incapacitating neurological disorder. Often, there are associated canonical sensory abnormalities, such as light and sound sensitivity, as well as associated nausea. Given this phenotype of disordered sensory processing and, in a third of patients, the phenomenon called aura accompanying migraine attacks, it has been suggested that the pathophysiology of migraine is likely to involve glutamate, the main excitatory neurotransmitter in the central nervous system (CNS). Glutamate plays a role in nociception, central sensitization, and cortical spreading depression (CSD), three processes that are deemed important in migraine biology. With an emphasis on the therapeutic potential of targeting various glutamate receptors in migraine, this review will discuss the currently available literature and emerging findings on the role of targeting glutamatergic pathways for the treatment of migraine. A thorough literature review was carried out on the functions of both metabotropic glutamate receptors (mGluRs), and the ionotropic glutamate receptors (NMDA, AMPA, and kainate) in migraine pathogenesis. The ever-present need for new treatments, the role of glutamate in the migraine aura phenomenon, and the consequences of monogenic migraine mutations on mediating prolonged, complex, or permanent aura are all discussed, culminating in a suggestion that glutamatergic targeting may hold particular promise in the management of migraine aura. There are plausible roles for metabotropic receptors in regulating pain processing in important migraine-related brain structures, like the thalamus and trigeminal nucleus. Similarly, ionotropic receptors contribute to excitatory neurotransmission and neuronal hyperexcitability. Recent studies have shown preclinical and early clinical results for treatments targeting these receptors, but there are still significant issues with treatment response, including drug transport, side effects, and efficacy. With ongoing and emerging discoveries in the field, there is increasing promise of new migraine medications targeting glutamate receptors. For bench to bedside translation in this area, continued study of the molecular basis of migraine, receptor subtypes, and exploration of potential drug delivery methods are needed.
- 11 March 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (5) , e210235
Consensus Recommendations to Establish Reporting Standards in fMRI of Migraine
Migraine is a multifaceted primary headache disorder. In neuroimaging of migraine, fMRI has been used to elucidate pathophysiology or monitor treatment effects. The current literature, however, is highly heterogeneous regarding reported variables and methodologies. This begets a lack of comparability and complicates synthesis of results across studies. We developed a framework for standardized reporting of fMRI studies in migraine. Experts on fMRI in migraine were identified from the literature and subjected to structured questionnaires in 2 iterations of 3 rounds according to the DELPHI method. A total of 157 statements across 17 reporting domains were rated on 5-point Likert scales (strong support to strong opposition). The first iteration covered demographic data, migraine-specific factors, medication, scan timing, healthy controls (HCs), participant sampling/recruiting, standardized forms, study preregistration, region of interest (ROI) analyses, validation data sets, data sharing, preprocessing documentation, and analysis software. The second iteration of the questionnaire covered scanner-related factors, sequence-related factors, physiology monitoring, and stimulation-related factors. Items showing strong consensus/consensus (≥90%/≥75% of participants indicating scores 4 or 5) were included as standard reporting items. All 3 rounds of the first/second iteration were completed by 29 and 26 researchers (age 46 ± 11 years; 38% female/age 46 ± 12 years; 44% female) from 23 and 21 institutions. Across both iterations, strong consensus and consensus was achieved for 34 (3 scanner-related factors, 9 sequence-related factors, 1 stimulation-related factor, 2 demographic factors, 7 migraine-specific factors, 2 medication-factors, 2 scan timing factors, 4 HC factors, 1 preregistration factor, 1 analysis software factor, and 2 ROI analyses factors) and 33 (1 scanner-related factors, 4 sequence related factors, 1 factor related to physiology monitoring, 1 stimulation-related factor, 3 demographic factors, 6 migraine-specific factors, 4 medication factors, 3 HC factors, 2 sampling factors, 1 standardized form, 1 preregistration factor, 1 data sharing factor, 2 analysis software factors, and 3 ROI analyses factors) items, respectively. From these, a checklist covering 63 items from 14 reporting domains was created. We present an expert-based framework for reporting standards in fMRI studies of migraine, which can be used for future studies to homogenize cohort characterization, fMRI acquisitions, and analysis protocols.
- 11 March 2025
- Published by Wolters Kluwer Health in Neurology
- Vol. 104 (5) , e210235
Consensus Recommendations to Establish Reporting Standards in fMRI of Migraine
Migraine is a multifaceted primary headache disorder. In neuroimaging of migraine, fMRI has been used to elucidate pathophysiology or monitor treatment effects. The current literature, however, is highly heterogeneous regarding reported variables and methodologies. This begets a lack of comparability and complicates synthesis of results across studies. We developed a framework for standardized reporting of fMRI studies in migraine. Experts on fMRI in migraine were identified from the literature and subjected to structured questionnaires in 2 iterations of 3 rounds according to the DELPHI method. A total of 157 statements across 17 reporting domains were rated on 5-point Likert scales (strong support to strong opposition). The first iteration covered demographic data, migraine-specific factors, medication, scan timing, healthy controls (HCs), participant sampling/recruiting, standardized forms, study preregistration, region of interest (ROI) analyses, validation data sets, data sharing, preprocessing documentation, and analysis software. The second iteration of the questionnaire covered scanner-related factors, sequence-related factors, physiology monitoring, and stimulation-related factors. Items showing strong consensus/consensus (≥90%/≥75% of participants indicating scores 4 or 5) were included as standard reporting items. All 3 rounds of the first/second iteration were completed by 29 and 26 researchers (age 46 ± 11 years; 38% female/age 46 ± 12 years; 44% female) from 23 and 21 institutions. Across both iterations, strong consensus and consensus was achieved for 34 (3 scanner-related factors, 9 sequence-related factors, 1 stimulation-related factor, 2 demographic factors, 7 migraine-specific factors, 2 medication-factors, 2 scan timing factors, 4 HC factors, 1 preregistration factor, 1 analysis software factor, and 2 ROI analyses factors) and 33 (1 scanner-related factors, 4 sequence related factors, 1 factor related to physiology monitoring, 1 stimulation-related factor, 3 demographic factors, 6 migraine-specific factors, 4 medication factors, 3 HC factors, 2 sampling factors, 1 standardized form, 1 preregistration factor, 1 data sharing factor, 2 analysis software factors, and 3 ROI analyses factors) items, respectively. From these, a checklist covering 63 items from 14 reporting domains was created. We present an expert-based framework for reporting standards in fMRI studies of migraine, which can be used for future studies to homogenize cohort characterization, fMRI acquisitions, and analysis protocols.
- 31 May 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (7) , 533-546
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy
Migraine is a common brain condition characterised by disabling attacks of headache with sensory sensitivities. Despite increasing understanding of migraine neurobiology and the impacts of this on therapeutic developments, there remains a need for treatment options for patients underserved by currently available therapies. The first specific drugs developed to treat migraine acutely, the serotonin-5-hydroxytryptamine [5-HT1B/1D] receptor agonists (triptans), seem to require headache onset in order to have an effect, while early treatment during mild pain before headache escalation improves short-term and long-term outcomes. Some patients find treating in the early window once headache has started but not escalated difficult, and migraine can arise from sleep or in the early hours of the morning, making prompt treatment after pain onset challenging. Triptans may be deemed unsuitable for use in patients with vascular disease and in those of older age and may not be effective in a proportion of patients. Headache is also increasingly recognised as being just one of the many facets of the migraine attack, and for some patients it is not the most disabling symptom. In many patients, painless symptoms can start prior to headache onset and can reliably warn of impending headache. There is, therefore, a need to identify therapeutic targets and agents that may be used as early as possible in the course of the attack, to prevent headache onset before it starts, and to reduce both headache and non-headache related attack burden. Early small studies using domperidone, naratriptan and dihydroergotamine have suggested that this approach could be useful; these studies were methodologically less rigorous than modern day treatment studies, of small sample size, and have not since been replicated. The emergence of novel targeted migraine treatments more recently, specifically calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), has reignited interest in this strategy, with encouraging results. This review summarises historical and emerging data in this area, supporting use of the premonitory phase as an opportunity to intervene as early as possible in migraine to prevent attack-related morbidity.
- 31 May 2024
- Published by Springer Nature in CNS Drugs
- Vol. 38 (7) , 533-546
Intervening in the Premonitory Phase to Prevent Migraine: Prospects for Pharmacotherapy
Migraine is a common brain condition characterised by disabling attacks of headache with sensory sensitivities. Despite increasing understanding of migraine neurobiology and the impacts of this on therapeutic developments, there remains a need for treatment options for patients underserved by currently available therapies. The first specific drugs developed to treat migraine acutely, the serotonin-5-hydroxytryptamine [5-HT1B/1D] receptor agonists (triptans), seem to require headache onset in order to have an effect, while early treatment during mild pain before headache escalation improves short-term and long-term outcomes. Some patients find treating in the early window once headache has started but not escalated difficult, and migraine can arise from sleep or in the early hours of the morning, making prompt treatment after pain onset challenging. Triptans may be deemed unsuitable for use in patients with vascular disease and in those of older age and may not be effective in a proportion of patients. Headache is also increasingly recognised as being just one of the many facets of the migraine attack, and for some patients it is not the most disabling symptom. In many patients, painless symptoms can start prior to headache onset and can reliably warn of impending headache. There is, therefore, a need to identify therapeutic targets and agents that may be used as early as possible in the course of the attack, to prevent headache onset before it starts, and to reduce both headache and non-headache related attack burden. Early small studies using domperidone, naratriptan and dihydroergotamine have suggested that this approach could be useful; these studies were methodologically less rigorous than modern day treatment studies, of small sample size, and have not since been replicated. The emergence of novel targeted migraine treatments more recently, specifically calcitonin gene-related peptide (CGRP) receptor antagonists (gepants), has reignited interest in this strategy, with encouraging results. This review summarises historical and emerging data in this area, supporting use of the premonitory phase as an opportunity to intervene as early as possible in migraine to prevent attack-related morbidity.
- Open Access
- 3 April 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 156, 33-40
Extended Phenotyping of Migraine in Children: A Cross-Sectional Study in a Specialist Children's Headache Clinic
- 3 April 2024
- Published by Elsevier in Pediatric Neurology
- Vol. 156, 33-40
Open AccessExtended Phenotyping of Migraine in Children: A Cross-Sectional Study in a Specialist Children's Headache Clinic
- 1 April 2024
- Published by Wolters Kluwer Health in Continuum
- Vol. 30 (2) , 325-343
Pathophysiology of Migraine
Rch, including human experimental migraine models and functional neuroimaging, have provided novel insights into migraine attack initiation, neurochemistry, neuroanatomy, and therapeutic substrates. It has become clear that migraine is a neural disorder, in which a wide range of brain areas and neurochemical systems are implicated, producing a heterogeneous clinical phenotype. Many of these neural pathways are monoaminergic and peptidergic, such as those involving calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide. We are currently witnessing an exciting era in which specific drugs targeting these pathways have shown promise in treating migraine, including some studies suggesting efficacy before headache has even started. Essential Points Migraine is a brain disorder involving both headache and altered sensory, limbic, and homeostatic processing. A complex interplay between neurotransmitter systems, physiologic systems, and pain processing likely occurs. Targeting various therapeutic substrates within these networks provides an exciting avenue for future migraine therapeutics....
- 1 April 2024
- Published by Wolters Kluwer Health in Continuum
- Vol. 30 (2) , 325-343
Pathophysiology of Migraine
Rch, including human experimental migraine models and functional neuroimaging, have provided novel insights into migraine attack initiation, neurochemistry, neuroanatomy, and therapeutic substrates. It has become clear that migraine is a neural disorder, in which a wide range of brain areas and neurochemical systems are implicated, producing a heterogeneous clinical phenotype. Many of these neural pathways are monoaminergic and peptidergic, such as those involving calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide. We are currently witnessing an exciting era in which specific drugs targeting these pathways have shown promise in treating migraine, including some studies suggesting efficacy before headache has even started. Essential Points Migraine is a brain disorder involving both headache and altered sensory, limbic, and homeostatic processing. A complex interplay between neurotransmitter systems, physiologic systems, and pain processing likely occurs. Targeting various therapeutic substrates within these networks provides an exciting avenue for future migraine therapeutics....